ferroxidase Inhibitors
2 drugsAbout ferroxidase
Ferroxidase, also known as ceruloplasmin, is an enzyme that facilitates iron metabolism by oxidizing ferrous iron (Fe2+) to ferric iron (Fe3+), enabling its binding to transferrin for transport. This process is crucial for maintaining iron homeostasis in the bloodstream.
Dysregulation of iron levels is implicated in various conditions, making ferroxidase a potential therapeutic target. Currently, there is no genetic evidence directly linking ferroxidase to specific diseases, but its role in iron homeostasis suggests therapeutic value.
Ferroxidase is targeted by two FDA-approved small molecule drugs: MULTRYS and TRALEMENT, both developed by AM REGENT. These drugs are approved for other therapeutic areas, highlighting the feasibility of targeting this enzyme.
Top ferroxidase Drugs
AM REGENT is the only company with approved drugs targeting ferroxidase.
The lack of competition suggests a high barrier to entry or an unvalidated market.
ferroxidase Drug Modality Landscape
Modalities
Routes of Administration
ferroxidase is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or biologics could provide a competitive advantage.
ferroxidase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ferroxidase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ferroxidase Drug Approval Timeline (2020 - 2020)
The first drug targeting ferroxidase was approved in 2020, with the most recent approval also in 2020.
The recent approvals suggest a renewed interest in ferroxidase, but the lack of subsequent approvals may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ferroxidase. A trial counts if an approved drug acting on ferroxidase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.